The P-IV IXORA-R study involves assessing of Taltz vs Tremfya (guselkumab) in 1-027 patients with moderate to severe plaque psoriasis for a total of 24 wks.- with the primary analysis conducted at 12 wks.
The P-IV IXORA-R study results: met its 1EPs & 2EPs i.e- complete skin clearance as measured by PASI 100 @12wks. (41.3% vs 24.9%) & superior to Tremfya in achieving PASI 75 @2wk.- PASI 90 @4 & 8 wks.- PASI 100 @4- 8 & 24wks.- sPGA 0 @12wk. and PASI 50 @1wk. respectively
Taltz is mAb targeting IL-17A cytokine and inhibits its interaction with the IL-17 receptor- thus inhibiting pro-inflammatory cytokines and chemokines while Tremfya is a mAb targeting p19 subunit of IL-23 and has received the FDA’s approval for mod. to sev. plaque psoriasis in July’2017
Click here to read full press release/ article
Ref: Eli Lilly | Image: Eli Lilly
